Safety and immunogenicity of a Vero-cell-derived, inactivated Japanese encephalitis vaccine: a non-inferiority, phase III, randomised controlled trial von Tauber, E, MD, Kollaritsch, H, MD, Korinek, M, MD, Rendi-Wagner, P, MD, Jilma, B, Dr, Firbas, C, MD, Schranz, S, MD, Jong, E, MD, Klingler, A, PhD, Dewasthaly, S, MD, Klade, CS, PhD

Volltext

Immunogenicity and safety of IXIARO® (IC51) in a Phase II study in healthy Indian children between 1 and 3 years of age von Kaltenböck, A, Dubischar-Kastner, K, Schuller, E, Datla, Mahima, Klade, C.S, Kishore, T.S.A

Volltext

Cross-genotype-reactivity of the immunodominant HCV CD8 T-cell epitope NS3-1073 von Fytili, P, Dalekos, G.N, Schlaphoff, V, Suneetha, P.V, Sarrazin, C, Zauner, W, Zachou, K, Berg, T, Manns, M.P, Klade, C.S, Cornberg, M, Wedemeyer, H

Volltext

Long-term immunogenicity of the new Vero cell-derived, inactivated Japanese encephalitis virus vaccine IC51 Six and 12 month results of a multicenter follow-up phase 3 study von SCHULLER, E, JILMA, B, VOICU, V, GOLOR, G, KOLLARITSCH, H, KALTENBÖCK, A, KLADE, C, TAUBER, E

Volltext

S196: ROPEGINTERFERON ALFA‐2B ACHIEVES PATIENT‐SPECIFIC TREATMENT GOALS IN POLYCYTHEMIA VERA: FINAL RESULTS FROM THE PROUD‐PV/CONTINUATION‐PV STUDIES von Gisslinger, H., Klade, C., Georgiev, P., Krochmalczyk, D., Gercheva‐Kyuchukova, L., Egyed, M., Dulicek, P., Illes, A., Pylypenko, H., Sivcheva, L., Mayer, J., Yablokova, V., Empson, V., Krejcy, K., Hasselbalch, H., Kralovics, R., Kiladjian, J.‐J.

Volltext

Hepatitis C virus-specific T cell responses against conserved regions in recovered patients von Klade, C.S, Kubitschke, A, Stauber, R.E, Meyer, M.F, Zinke, S, Wiegand, J, Zauner, W, Aslan, N, Lehmann, M, Cornberg, M, Manns, M.P, Reisner, P, Wedemeyer, H

Volltext

Safety and immunogenicity of concomitant vaccination with the cell-culture based Japanese Encephalitis vaccine IC51 and the hepatitis A vaccine HAVRIX1440 in healthy subjects: A si... von Kaltenböck, A, Dubischar-Kastner, K, Eder, G, Jilg, W, Klade, C, Kollaritsch, H, Paulke-Korinek, M, von Sonnenburg, F, Spruth, M, Tauber, E, Wiedermann, U, Schuller, E

Volltext

Safety and immunogenicity of concomitant vaccination with the cell-culture based Japanese Encephalitis vaccine IC51 and the hepatitis A vaccine HAVRIX® 1440 in healthy subjects: A... von Kaltenböck, A, Dubischar-Kastner, K, Eder, G, Jilg, W, Klade, C, Kollaritsch, H, Paulke-Korinek, M, von Sonnenburg, F, Spruth, M, Tauber, E, Wiedermann, U, Schuller, E

Volltext

Identification of vaccine candidate antigens of Staphylococcus aureus by serological proteome analysis von Vytvytska, Oresta, Nagy, Eszter, Blüggel, Martin, Meyer, Helmut E., Kurzbauer, Robert, Huber, Lukas A., Klade, Christoph S.

Volltext

1203 CLONAL SEQUENCING OF HCV NS3 PROTEASE AND HELICASE T CELL EPITOPES IN PATIENTS IMMUNIZED WITH THE THERAPEUTIC HCV VACCINE IC41 von Dietz, J, Boehm, T, Füller, C, Zeuzem, S, Sarrazin, C, Klade, C

Volltext

Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study (vol 7,... von Gisslinger, H., Klade, C., Georgiev, P.

Volltext

Long term immunogenicity following a booster dose of the inactivated Japanese encephalitis vaccine IXIARO®, IC51 von Dubischar-Kastner, K.L, Eder, S, Jelinek, T, Jilma, B, Kaltenboeck, A, Kollaritsch, H, Schuller, E, Klade, C

Volltext

Long-term immunogenicity of the new Vero cell-derived, inactivated Japanese encephalitis virus vaccine IC51 von Schuller, E, Jilma, B, Voicu, V, Golor, G, Kollaritsch, H, Kaltenböck, A, Klade, C, Tauber, E

Volltext

Identification of tumor antigens in renal cell carcinoma by serological proteome analysis von Klade, Christoph S., Voss, Tilman, Krystek, Edeltraud, Ahorn, Horst, Zatloukal, Kurt, Pummer, Karl, Adolf, Günther R.

Volltext

PS1457 MAINTENANCE OF RESPONSE IN LONG‐TERM TREATMENT WITH ROPEGINTERFERON ALFA‐2B (BESREMI®) VS. HYDROXYUREA IN POLYCYTHEMIA VERA PATIENTS (PROUD/CONTINUATION‐PV PHASE III TRIALS)... von Gisslinger, H., Klade, C., Georgiev, P., Krochmalczyk, D., Gercheva‐Kyuchukova, L., Egyed, M., Rossiev, V., Dulicek, P., illes, A., Pylypenko, H., Sivcheva, L., Mayer, J., Yablokova, V., Krejcy, K., Grohmann‐Izay, B., Maurer, G., Hasselbalch, H.C., Kralovics, R., Kiladjian, J.‐J.

Volltext

A new synthesis of substituted furans von Danheiser, Rick L, Stoner, Eric J, Koyama, Hiroo, Yamashita, Dennis S, Klade, Carrie A

Volltext

14 Cross-genotype-reactivity of the immunodominant HCV-CD8 T-cell epitope NS3-1073: Significance for the development of peptide-based vaccines against HCV von Fytili, P., Dalekos, G., Cornberg, M., Schlaphoff, V., Zauner, W., Zachou, K., Manns, M.P., Klade, C., Wedemeyer, H.

Volltext

Safety and immunogenicity of a Vero-cell-derived, inactivated Japanese encephalitis vaccine : a non-inferiority, phase III , randomised controlled trial. Commentary von FISCHER, Marc, CASEY, Christine, JONG, E, KLINGLER, A, DEWASTHALY, S, KLADE, C. S, CHEN, Robert T, TAUBER, E, KOLLARITSCH, H, KORINEK, M, RENDI-WAGNER, P, JILMA, B, FIRBAS, C, SCHRANZ, S

Volltext

Landiolol in patients with septic shock resident in an intensive care unit (LANDI-SEP): study protocol for a randomized controlled trial von Unger, M, Morelli, A, Singer, M, Radermacher, P, Rehberg, S, Trimmel, H, Joannidis, M, Heinz, G, Cerny, V, Dostál, P, Siebers, C, Guarracino, F, Pratesi, F, Biancofiore, G, Girardis, M, Kadlecova, P, Bouvet, O, Zörer, M, Grohmann-Izay, B, Krejcy, K, Klade, C, Krumpl, G

Volltext bestellen

Tolérance, immunogénicité et confirmation de dose pour le vaccin inactivé contre le virus de l'Encéphalite Japonaise, Ixiaro®, IC51, chez des enfants philippins âgés de 3 à < 12 an... von MONCHECOURT, F, DUBISCHAR-KASTNER, K, KLADE, C, KADLECEK, V, SABLAN, B, FAY BORJA-TABORA, C, GATCHALIAN, S, EDER, S, SCHULLER, E, TAUCHER, C, WESTRITSCHNIG, K

Volltext